Key facts
- This page summarizes Marc L. Panoff's Form 3 filing for LB PHARMACEUTICALS INC.
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 29 Sep 2025, 20:12.
Marc L. Panoff - 10 Sep 2025 Form 3 Insider Report for LB PHARMACEUTICALS INC
- Reporting relationship
- Senior Vice President, Finance
- Issuer ticker
- LBRX on Nasdaq
- Reported as of
- 10 Sep 2025
- Net transaction value
- $0
- Reporting owner signature
- /s/ Marc Panoff
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Marc L. Panoff filed Form 3 for LB PHARMACEUTICALS INC on 29 Sep 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001304340
Primary reporting owner
PANOFF MARC L
- Relationship
- Senior Vice President, Finance
- Address
- C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK
- Signature
- /s/ Marc Panoff
- Signature date
- 10 Sep 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LBRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,242
- Date
- 10 Sep 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LBRX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,944
- Exercise price
- $64.15
- Footnotes
- F1
LBRX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 896
- Exercise price
- $69.72
- Footnotes
- F1
LBRX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,255
- Exercise price
- $69.72
- Footnotes
- F1
LBRX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,343
- Exercise price
- $41.84
- Footnotes
- F2
LBRX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,171
- Exercise price
- $41.84
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Immediately exercisable.
Footnote F2
One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Footnote F3
One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.